• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-1/A filed by IBO (Listing Market - NYSE Amex Network B F)

    8/27/24 4:06:04 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBO alert in real time by email
    S-1/A 1 forms-1a.htm

     

    As filed with the Securities and Exchange Commission on August 27, 2024

     

    Registration No. 333-275062

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Amendment No. 7 to

    FORM S-1

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    IMPACT BIOMEDICAL INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada   8731   85-3926944

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification Number)

     

    1400 Broadfield Blvd., Suite 130

    Houston, TX 77084

    Tel: (585) 325-3610

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Frank D. Heuszel

    Chief Executive Officer

    Impact BioMedical Inc.

    1400 Broadfield Blvd., Suite 130

    Houston, TX 77084

    Tel: (585) 325-3610

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    With copies to:

     

    Darrin M. Ocasio, Esq. Joseph M. Lucosky, Esq.
    Sichenzia Ross Ference Carmel LLP Lucosky Brookman LLP
    1185 Avenue of the Americas, 31 Fl. 101 Wood Avenue South, 5th Floor
    New York, NY 10036 Woodbridge, NJ 08830
    Tel: (212) 930-9700 Tel: (732) 395-4400
    Fax: (212) 930-9725 Fax: (732) 395-4401

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by a check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

     

    Large Accelerated Filer ☐ Accelerated Filer ☐
    Non-Accelerated Filer ☒ Smaller Reporting Company ☒
      Emerging Growth Company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     
     

     


    EXPLANATORY NOTE

     

    This Amendment to the Registration Statement on Form S-1 (File No. 333-275062) is filed solely to amend Item 13 of Part II thereof. Accordingly, this Amendment consists only of the facing page, this explanatory note, Part II, Item 13, and the signature page. This Amendment does not modify any provision of the preliminary prospectus contained in Part I. Accordingly, the preliminary prospectus has been omitted.

     

     
     

     

    PART II — INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 13. Other Expenses of Issuance and Distribution

     

    The following table sets forth an itemization of the various expenses, all of which we will pay, in connection with the issuance and distribution of the securities being registered. All of the amounts shown are estimated except the SEC registration fee and the FINRA filing fee.

     

    SEC registration fee  $ 2,435.40  
    FINRA filing fee  $

    2,975.00

     
    NYSE American listing fee  $ 60,000.00  
    Legal fees and expenses  $ 125,000.00  
    Accounting fees and expenses  $ 15,000.00  
    Transfer agent and registrar fees  $ 5,500.00  
    Miscellaneous fees and expenses  $ 41,089.60  
    Total  $ 252,000.00  

     

    II-1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the town of West Henrietta, New York on the 27th day of August 2024.

     

      IMPACT BIOMEDICAL INC.
         
      By: /s/ Frank D. Heuszel
      Name:  Frank D. Heuszel
      Title: President
         
    Dated: August 27, 2024    

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Frank D. Heuszel, as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Frank D. Heuszel        
    Frank D. Heuszel  

    Chairman of the Board, Chief Executive Officer (Principal Executive Officer) and

    President

      August 27, 2024
             
    /s/ Jason Grady        
    Jason Grady   Director   August 27, 2024
             
    /s/ Todd D. Macko        
    Todd D. Macko   Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer   August 27, 2024
             
    /s/ Mark Suseck        
    Mark Suseck   Chief Operating Officer   August 27, 2024
             
    /s/ Dr. Elise Brownell        
    Dr. Elise Brownell   Director   August 27, 2024
             
    /s/ Melissa Sims        
    Melissa Sims   Director   August 27, 2024
             
    /s/ Castel Hibbert        
    Castel Hibbert   Director   August 27, 2024
             
    /s/ Christian Zimmerman        
    Christian Zimmerman   Director   August 27, 2024
             
    /s/ David Keene        
    David Keene   Director   August 27, 2024

     

    II-2
    Get the next $IBO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IBO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IBO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Dss, Inc. sold $88,006 worth of shares (161,000 units at $0.55), decreasing direct ownership by 23% to 545,024 units (SEC Form 4)

    4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

    1/6/26 5:25:05 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dss, Inc. sold $845,013 worth of shares (890,800 units at $0.95), decreasing direct ownership by 85% to 161,100 units (SEC Form 4)

    4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

    4/7/25 9:59:28 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chan Heng Fai Ambrose sold $174,020 worth of shares (351,555 units at $0.49) (SEC Form 4)

    4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

    4/7/25 5:18:49 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Dss, Inc. sold $249,408 worth of shares (53,300 units at $4.68) and bought $310 worth of shares (200 units at $1.55) (SEC Form 4)

    4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

    3/24/25 8:00:38 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Heuszel Frank D bought $1,129 worth of shares (500 units at $2.26), increasing direct ownership by 0.52% to 97,344 units (SEC Form 4)

    4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

    12/9/24 4:05:17 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Heuszel Frank D bought $1,305 worth of shares (500 units at $2.61), increasing direct ownership by 0.52% to 96,844 units (SEC Form 4)

    4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

    12/3/24 9:51:36 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBO
    SEC Filings

    View All

    SEC Form DEF 14C filed by Impact BioMedical Inc.

    DEF 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

    12/30/25 4:30:27 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14C filed by Impact BioMedical Inc.

    PRE 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

    12/11/25 5:11:47 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Impact BioMedical Inc.

    10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

    11/7/25 4:30:48 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue

    HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition and Method of Controlling Infectious Diseases with Functional Fragrances," developed within IBO's 3F™ technology platform. This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by plants, with potential application as an antibacterial or antiviral agent. This patent will expire on December 7, 2038. This expands Impact Biomedical's 3F™ patent estate which include

    8/18/25 8:30:00 AM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

    A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr Ashleys"), and Impact BioMedical Inc. ("Impact BioMedical") (NYSE:IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American ("Impact BioMedical", together with Dr Ashleys, the "Parties"), are pleased to announce the execution of a merger and share exchange agreement (the "Merger Agreement") on June 21, 2025 to enter into a strategic merger transaction (the "Transaction"). Upon closing of the Transaction, Dr. Ashleys will acquire Impact B

    6/23/25 7:52:44 AM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Impact Biomedical Inc. Announcement Stock Activity/Pricing

    HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. About Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE:IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through re

    3/21/25 2:38:33 PM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBO
    Leadership Updates

    Live Leadership Updates

    View All

    Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

    A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr Ashleys"), and Impact BioMedical Inc. ("Impact BioMedical") (NYSE:IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American ("Impact BioMedical", together with Dr Ashleys, the "Parties"), are pleased to announce the execution of a merger and share exchange agreement (the "Merger Agreement") on June 21, 2025 to enter into a strategic merger transaction (the "Transaction"). Upon closing of the Transaction, Dr. Ashleys will acquire Impact B

    6/23/25 7:52:44 AM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBO
    Financials

    Live finance-specific insights

    View All

    Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"

    HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approximately $1.15 million. This acquisition aligns with Impact Biomedical's focused roll-up strategy, expanding its portfolio with cutting-edge solutions that will generate immediate revenue while reinforcing its commitment to human health and wellness. Celios® brings advanced air purification capability, featuring design, system, and method patents

    2/26/25 8:30:00 AM ET
    $IBO
    Biotechnology: Pharmaceutical Preparations
    Health Care